Lilly and Novartis face drug ad dispute; the biggest questions about the FDA's accelerated approval changes

Taking stock of the drug industry, from the lab to the medicine chest‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

January 25, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad Experts said the BBB involvement in the Lilly and Novartis dispute indicates companies are frustrated with FDA inaction on drug ads. By Ed Silverman STAT+ | Novartis is fined by Belgian regulators for anticompetitive practices over an eye treatment The fine is only the latest act in a long-running drama involving Lucentis and Avastin, both used to treat age-related macular degeneration. By Ed Silverman The drug was meant to save children's lives. Instead, they're dying Substandard asparaginase, a childhood leukemia drug, has been shipped to more than 90 countries, overwhelmingly from companies in India. By Rosa Furneaux and Laura Margottini — TBIJ STAT STAT+ | The 4 biggest questions about the FDA's forthcoming changes to accelerated approvals Congress just boosted the FDA's authority over the post-market clinical trials that are a condition of speedy drug approvals. By John Wilkerson STAT+ | Vir CEO George Scangos to retire, after pandemic success George Scangos, 74, will retire after nearly 40 itinerant years, including at Bayer and a turnaround stint at Biogen. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser